{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-115011","form_type":"8-K","ticker":"QURE","cik":"0001590560","company_name":"uniQure N.V.","filed_at":"2023-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.670563+00:00","generated_at":"2026-06-08T15:24:08.411149+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"uniQure Q3 net loss widens to $89.6M ($1.88/sh); cash at $659M","bullets":["Net loss of $89.6M ($1.88 diluted EPS) vs $47.9M ($1.02 EPS) in Q3 2022; revenue flat at $1.4M.","Cash and investments $658.9M as of Sept 30, 2023; $180M cost savings expected to fund ops into Q2 2027.","FDA cleared IND for AMT-260 (epilepsy); AMT-130 (Huntington's) update expected later Q4 2023.","Strategic reorganization: 28% workforce cut, CSO Ricardo Dolmetsch departs, Richard Porter becomes Chief Business & Scientific Officer.","Received $100M milestone from CSL for first U.S. HEMGENIX sale; won 2023 Prix Galien USA Award."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-115011","json":"https://secwatch.observer/filing/0001104659-23-115011.json","markdown":"https://secwatch.observer/filing/0001104659-23-115011.md","text":"https://secwatch.observer/filing/0001104659-23-115011.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1590560/000110465923115011/0001104659-23-115011-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1590560/000110465923115011/tm2330023d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T15:24:08.411149+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6b1ed352047d7060ded93d2f5b6c73ea70050416","claim":"uniQure N.V. reported financial results for the quarter ended September 30, 2023.","evidence_excerpt":"On November 7, 2023, uniQure N.V. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1590560/000110465923115011/0001104659-23-115011-index.htm","confidence":0.98,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}